Allogene Therapeutics/$ALLO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Allogene Therapeutics
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
- Ticker
- $ALLO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 151
- Headquarters
- South San Francisco, United States
- Website
- allogene.com
ALLO Metrics
BasicAdvanced
$312M
-
-$0.61
0.78
-
Price and volume
Market cap
$312M
Beta
0.78
52-week high
$4.46
52-week low
$0.88
Average daily volume
9.2M
Financial strength
Current ratio
7.788
Quick ratio
7.667
Long term debt to equity
0.173
Total debt to equity
0.181
Interest coverage (TTM)
-145.03%
Profitability
EBITDA (TTM)
-182.452
Gross margin (TTM)
-2,839.44%
Net profit margin (TTM)
-3,759.98%
Operating margin (TTM)
-4,099.33%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-25.45%
Return on equity (TTM)
-49.29%
Valuation
Price to revenue (TTM)
55.381
Price to book
0.71
Price to tangible book (TTM)
0.71
Price to free cash flow (TTM)
-2.363
Free cash flow yield (TTM)
-42.32%
Free cash flow per share (TTM)
-0.381
Growth
Earnings per share change (TTM)
-37.52%
3-year revenue growth (CAGR)
414.85%
3-year earnings per share growth (CAGR)
-35.53%
What the Analysts think about ALLO
Analyst ratings (Buy, Hold, Sell) for Allogene Therapeutics stock.
Analyst projections of the future price of Allogene Therapeutics stock.
Bulls say / Bears say
In ALPHA3, 58.3% of patients on cema-cel became MRD-negative, versus 16.7% under observation; the FDA has granted the programme RMAT and Fast Track designations. The early signal and regulatory engagement support its potential in first-line lymphoma treatment. (U.S. Securities and Exchange Commission, RTTNews)
ALLO-316 showed a 31% confirmed response rate at its recommended Phase 2 dose in patients with CD70-high kidney cancer, with all responders still progression-free at the analysis. This is encouraging early evidence that Allogene’s cell therapy approach may work in solid tumours. (Allogene Therapeutics)
Allogene reported $423.6 million in cash and investments at the end of June 2026 and expects its runway to extend into 2029. That should fund several key clinical read-outs before the company needs to seek further financing. (GlobeNewswire)
The ALPHA3 MRD result came from just 12 patients in each arm, and MRD clearance is not yet proof that patients live longer without their cancer returning. The event-free survival analysis, which could establish clinical benefit, is still ahead. (U.S. Securities and Exchange Commission, Investing.com)
The ALLO-316 response result is from an early-stage study in a selected group of patients whose tumours had high CD70 expression. Its effectiveness in a broader population, and its path to a commercially useful treatment, remain uncertain. (Allogene Therapeutics)
Allogene has no established commercial business and reported a cumulative deficit of about $2.1 billion by June 2026. It says it may need more capital to carry out its plans, leaving investors exposed to further share dilution or delays if funding is harder to secure. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 16 Oct 2026.
ALLO Financial Performance
Revenues and expenses
ALLO Earnings Performance
Company profitability
Upcoming events
No upcoming events
ALLO News
AllArticlesVideos
Funds containing ALLO
Fund name | Fund size | $ALLO weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.02% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | $5B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.